NWBOOTCPharmaceutical PreparationsFiscal year ends December 31

NORTHWEST BIOTHERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.16−0.00 (-0.88%)

Close on Oct 19, 2026

Community

Notes and questions about Northwest Biotherapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Northwest Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-16000 reverse split on Nov 14, 2012
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NWBO.

Revenue growth98.6% · median 12.8%

Operating margin-2316.1% · median -3301.2%

Net margin-1736.4% · median -3102.7%

Advertisement
300 × 250